Endocrinology and metabolism Archives - Page 2 of 6

An assessment of clinically important differences on the worst pain severity item of the modified brief pain inventory in patients with diabetic peripheral neuropathic pain

Authors: J Marcus, K Lasch, Y Wan, M Yang, C Hsu, D Merante Published: Pain Research and Management, 2018 View publication Objectives Using patient global impression of change (PGIC) as an anchor,...

Cross-cultural validity of the thyroid-specific quality-of-life patient-reported outcome measure, ThyPRO

Authors: T Watt, G Barbesino, J B Bjorner, S J Bonnema, B Bukvic, R Drummond, M Groenvold, L Hegedüs, V Kantzer, K E Lasch, C Marcocci, A Mishra, R Netea-Maier, M Ekker,...

Cost-effectiveness analysis of saxagliptin as oral triple therapy (with metformin and a sulfonylurea) in the management of type 2 diabetes in Spain

Authors: J Sánchez-Covisa, J Franch, D Mauricio, N López-Martínez, L-H Chuang, M Capel Published: Pharmacoeconomics – Spanish Research Articles, 2016 View publication Objectives To evaluate the cost-effectiveness of saxagliptin versus sulfonylurea (glipizide)...

Cost-effectiveness of dapagliflozin versus dpp-4 inhibitors as monotherapy in the treatment of type 2 diabetes mellitus from a UK health care perspective

Authors: M Charokopou, P McEwan, S Lister, L Callan, K Bergenheim, K Tolley, R Postema, R Townsend, M Roudaut Published: Value in health : the journal of the International Society for Pharmacoeconomics...

Economic assessment of delaying insulin treatment through the use of newer anti-diabetic agents, dapagliflozin (Forxiga®) and exenatide (Bydureon®), both as add-on to metformin; a cost-effectiveness analysis from a Uk NHS perspective

Authors: M Charokopou, H Vioix, B G Verheggen, D Maddocks, T Bratt, D Franks Published: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2014 View...

Resource use and outcomes associated with initiation of injectable therapies for patients with type 2 diabetes mellitus

Authors: R Brice, S Shelley, P Chaturvedi, D Glah, D Ashley, M Hadi Published: Drugs in Context, 2015 View publication Introduction Management of type 2 diabetes mellitus (T2DM) often requires intervention with...

Systematic review and meta-analysis of pharmacological therapies for painful diabetic peripheral neuropathy

Authors: S J Snedecor, L Sudharshan, J C Cappelleri, A Sadosky, S Mehta, M Botteman Published: Pain Practice, 2014 View publication Background Painful diabetic peripheral neuropathy (pDPN) is prevalent among persons with...

Treatment patterns of anti-vascular endothelial growth factor and laser therapy among patients with diabetic macular edema

Authors: S Jiang, J C Barner, C Park, Y Ling Published: Journal of Managed Care & Specialty Pharmacy, 2015 View publication Background Diabetic macular edema (DME) is a form of diabetic retinopathy...

Cost efficiency of canagliflozin versus sitagliptin for type 2 diabetes mellitus

Authors: V U Ektare, J M S Lopez, S C Martin, D A Patel, M F T Rupnow, M F Botteman Published: The American Journal of Managed Care, 2014 View publication Objectives...

News